Pharmaceutical News and Articles

Supreme Court Blocks Colorado Limits on Therapy for LGBTQ Minors

WEDNESDAY, April 1, 2026 The U.S. Supreme Court has blocked a Colorado law that forbid mental health professionals from trying to change LGBTQ minors sexual ori

Trump Supports Surgeon General Pick Despite Senate Concerns

WEDNESDAY, April 1, 2026 The White House is standing behind its pick for surgeon general, even as questions about her nomination continue. President Donald Trum

Honey Almond Cream Cheese, Sold at Einstein Bros. Bagels, Recalled Due To Undeclared Nuts

WEDNESDAY, April 1, 2026 A popular cream cheese spread sold at Einstein Bros. Bagels locations is being recalled due to a labeling mix-up that could put people

Hundreds of U.S. Hospitals at Risk of Shutting Down From Medicaid Cuts

WEDNESDAY, April 1, 2026 A new analysis from Public Citizen found that 446 hospitals are at high risk of closing or cutting services due to planned Medicaid cut

ACC: Expanding Eligibility for Low-Income Subsidies Can Improve CVD Medication Adherence

Expanding eligibility for full low-income subsidies (LIS) to include those with incomes between 135 and 150 percent of the federal poverty level (FPL) is associ

Continuous Postoperative Monitoring Reduces Duration of Oxygen Desaturation

Continuous monitoring after noncardiac surgery is associated with a significant reduction in the duration of oxygen saturation less than 90 percent, according t

ACC: Mavacamten Efficacious for Adolescents With Obstructive Hypertrophic Cardiomyopathy

Mavacamten, the first-in-class cardiac myosin inhibitor approved for treatment of symptomatic adults with obstructive hypertrophic cardiomyopathy (HCM), is effi

FDA Approves Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can be Taken Any Time of Day Without Food or Water Restrictions

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study design

Efzimfotase Alfa Demonstrated Positive Results From Global Phase III Clinical Programme in Hypophosphatasia

The efzimfotase alfa (ALXN1850) Phase III clinical programme, designed to study a broad hypophosphatasia (HPP) patient population, demonstrated positive results